VINAY SINGH
The Burrill Report
Bristol-Myers Squibb has created a new International Immuno-Oncology Network, a collaboration between industry, universities, and research centers from around the world aimed at furthering the scientific understanding of immuno-oncology, or the human immune system’s potential to fight cancer.
In addition to Bristol-Myers Squibb, the collaboration consists of ten academic or cancer-research institutions from around the world including The Netherlands Cancer Institute, Dana-Farber Cancer Institute, The Royal Marsden NHS Foundation Trust, the Institute of Cancer Research, and Johns Hopkins Kimmel Cancer Center.
Collaborations between academia, private research institutions, and Big Pharma has become increasingly common as pharmaceutical companies continue to look outside their own walls to acquire promising new early-stage treatments and try to lessen both the risks and costs of developing such drugs.
http://www.burrillreport.com/article-bristol_myers_squibb_forms_the_international_immuno_oncology_network.html
“The public-private partnerships formed through the collaboration will leverage the intellectual capabilities of an extensive global network.”
In addition to Bristol-Myers Squibb, the collaboration consists of ten academic or cancer-research institutions from around the world including The Netherlands Cancer Institute, Dana-Farber Cancer Institute, The Royal Marsden NHS Foundation Trust, the Institute of Cancer Research, and Johns Hopkins Kimmel Cancer Center.
Collaborations between academia, private research institutions, and Big Pharma has become increasingly common as pharmaceutical companies continue to look outside their own walls to acquire promising new early-stage treatments and try to lessen both the risks and costs of developing such drugs.
http://www.burrillreport.com/article-bristol_myers_squibb_forms_the_international_immuno_oncology_network.html
No comments:
Post a Comment